This Harvard Medical School Continuing Education video examines these key questions: What role do GLP1 receptor agonists (GLP1 RA) play in weight loss? What are the risks and benefits of using GLP1 RA for weight loss?
Lee-Shing Chang, MD, an endocrinologist at Brigham and Women’s Hospital, identifies FDA-approved medications for weight loss and explains GLP1 and the role GLP1 receptor agonists play in weight management. Key studies including the SCALE and STEP trials are highlighted and the efficacy of the GLP-1 receptor agonists liraglutide and semaglutide are compared.
00:00 | Introduction
00:37 | Pharmacotherapy for weight management
01:25 | What is GLP1 and what does it do?
02:35 | Clinical trials of liraglutide and semaglutide for weight loss
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.
References:
Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605-628. doi:10.1038/nrneph.2017.123
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989. doi:10.1056/NEJMoa2032183
Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150.
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
Notice: At this time, the content in this video is not accredited.